Filtered By:
Condition: Obesity

This page shows you your search results in order of date. This is page number 11.

Order by Relevance | Date

Total 4516 results found since Jan 2013.

Impact of body mass index on efficacy and safety of ticagrelor versus clopidogrel in patients with minor stroke or transient ischemic attack
CMAJ. 2023 Jul 10;195(26):E897-E904. doi: 10.1503/cmaj.230262.ABSTRACTBACKGROUND: Body mass index (BMI) may affect the response to platelet P2Y12 receptor inhibitors. We aimed to explore whether BMI influenced the efficacy and safety of ticagrelor and clopidogrel for secondary prevention of minor ischemic stroke or transient ischemic attack (TIA) among patients enrolled in the CHANCE-2 (Ticagrelor or Clopidogrel with Aspirin in High-Risk Patients with Acute Nondisabling Cerebrovascular Events II) trial.METHODS: In a multicentre, randomized, double-blind, placebo-controlled trial, conducted in China, we randomized patients ...
Source: Canadian Medical Association Journal - July 10, 2023 Category: General Medicine Authors: Jia Zhang Anxin Wang Xue Tian Xia Meng Xuewei Xie Jing Jing Jinxi Lin Yilong Wang Zixiao Li Liping Liu Hao Li Yong Jiang Xingquan Zhao Yongjun Wang Source Type: research

Glucagon-like peptide-1 receptor agonists across the spectrum of heart failure
J Clin Endocrinol Metab. 2023 Jul 6:dgad398. doi: 10.1210/clinem/dgad398. Online ahead of print.ABSTRACTGlucagon-like peptide-1 receptor agonists (GLP-1 RA) have been used to reduce body weight in overweight or people with obesity and to improve glycemic control and cardiovascular outcomes among people with type 2 diabetes (T2D) and a high cardiovascular risk. However, the effects of GLP-1 RA may be modified by the presence of heart failure (HF). In this review, we summarize the evidence for the use of GLP-1 RA across patient's risk with a particular focus in HF. After a careful review of the literature, we challenge the c...
Source: The Journal of Clinical Endocrinology and Metabolism - July 6, 2023 Category: Endocrinology Authors: Jo ão Pedro Ferreira Abhinav Sharma Javed Butler Milton Packer Faiez Zannad Francisco Vasques-N óvoa Adelino Leite-Moreira Jo ão Sérgio Neves Source Type: research

Molecular Mechanisms of Lipid-Based Metabolic Adaptation Strategies in Response to Cold
Cells. 2023 May 10;12(10):1353. doi: 10.3390/cells12101353.ABSTRACTTemperature changes and periods of detrimental cold occur frequently for many organisms in their natural habitats. Homeothermic animals have evolved metabolic adaptation strategies to increase mitochondrial-based energy expenditure and heat production, largely relying on fat as a fuel source. Alternatively, certain species are able to repress their metabolism during cold periods and enter a state of decreased physiological activity known as torpor. By contrast, poikilotherms, which are unable to maintain their internal temperature, predominantly increase me...
Source: Cancer Control - July 6, 2023 Category: Cancer & Oncology Authors: Gang Wu Ralf Baumeister Thomas Heimbucher Source Type: research

Glucagon-like peptide-1 receptor agonists across the spectrum of heart failure
J Clin Endocrinol Metab. 2023 Jul 6:dgad398. doi: 10.1210/clinem/dgad398. Online ahead of print.ABSTRACTGlucagon-like peptide-1 receptor agonists (GLP-1 RA) have been used to reduce body weight in overweight or people with obesity and to improve glycemic control and cardiovascular outcomes among people with type 2 diabetes (T2D) and a high cardiovascular risk. However, the effects of GLP-1 RA may be modified by the presence of heart failure (HF). In this review, we summarize the evidence for the use of GLP-1 RA across patient's risk with a particular focus in HF. After a careful review of the literature, we challenge the c...
Source: The Journal of Clinical Endocrinology and Metabolism - July 6, 2023 Category: Endocrinology Authors: Jo ão Pedro Ferreira Abhinav Sharma Javed Butler Milton Packer Faiez Zannad Francisco Vasques-N óvoa Adelino Leite-Moreira Jo ão Sérgio Neves Source Type: research

Impact of comorbidities on health status measured using the Kansas City Cardiomyopathy Questionnaire in patients with HFrEF and HFpEF
ConclusionsCardiac and non-cardiac comorbidities are common in both HFrEF and HFpEF patients and most are associated with reductions in health status although the impact varied among comorbidities, by the number of comorbidities, and by HF phenotype. Treating/correcting comorbidity is a therapeutic approach that may improve the health status of patients with HF.This article is protected by copyright. All rights reserved.
Source: European Journal of Heart Failure - July 4, 2023 Category: Cardiology Authors: Mingming Yang, Toru Kondo, Carly Adamson, Jawad H. Butt, William T. Abraham, Akshay S. Desai, Karola S. Jering, Lars K øber, Mikhail N. Kosiborod, Milton Packer, Jean L. Rouleau, Scott D. Solomon, Muthiah Vaduganathan, Michael R. Zile, Pard Tags: Research Article Source Type: research

Risk factors for cardiovascular disease in primary Sj ögren’s syndrome (pSS): a 20-year follow-up study
ConclusionsExtraglandular involvement was associated with a higher prevalence of arterial hypertension, dyslipidemia, hyperuricemia, and coronary artery disease. Anti-Ro/SSA and anti-La/SSB seropositivity was associated with a higher prevalence of cardiac rhythm abnormalities, hyperuricemia, venous thrombosis, coronary artery disease, and cerebrovascular disease. Raised inflammatory markers, disease activity measured by ESSDAI, extraglandular involvement, serologic markers including hypergammaglobulinemia and low C3, and treatment with corticosteroids were associated with a higher risk for cardiovascular comorbidities.Key ...
Source: Clinical Rheumatology - July 4, 2023 Category: Rheumatology Source Type: research

Insulin Regulation of Hepatic Lipid Homeostasis
Compr Physiol. 2023 Jun 26;13(3):4785-4809. doi: 10.1002/cphy.c220015.ABSTRACTThe incidence of obesity, insulin resistance, and type II diabetes (T2DM) continues to rise worldwide. The liver is a central insulin-responsive metabolic organ that governs whole-body metabolic homeostasis. Therefore, defining the mechanisms underlying insulin action in the liver is essential to our understanding of the pathogenesis of insulin resistance. During periods of fasting, the liver catabolizes fatty acids and stored glycogen to meet the metabolic demands of the body. In postprandial conditions, insulin signals to the liver to store exc...
Source: Atherosclerosis - June 26, 2023 Category: Cardiology Authors: Kahealani Uehara Dominic Santoleri Anna E Garcia Whitlock Paul M Titchenell Source Type: research